Clinical and Experimental Pediatrics

Search

Search

Close


Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-11.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 93

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 94

All issues > Volume 44(11); 2001

Original Article
J Korean Pediatr Soc. 2001;44(11):1269-1277. Published online November 15, 2001.
Factors Related to Weight Changes in Epileptic Children Treated with Vigabatrin
Sang-Nam SN Bae1, Bong-Seok BS Choi1, Sang-Ook SO Nam1, Hee-Ju HJ Park1
1Department of Pediatrics, College of Medicine, Pusan National University, Pusan, Korea
Correspondence Sang-Ook SO Nam ,Email: weareone@hyowon.pusan.ac.kr
Abstract
Purpose
: This study was undertaken to investigate factors related to weight changes in children treated with vigabatrin(VGB).
Methods
: We have analyzed mean weight standard deviation scores(SDS) retrospectively and interviewed 35 childhood epileptic patients attending Pusan National University Hospital on VGB monotherapy followed over 36 months. Putative risk factors including sex, age, duration of VGB administration, mean weight SDS score at diagnosis, dose of VGB administration, seizure type (generalized or partial), and etiology(idipathic or symptomatic) were statistically analyzed.
Results
: Thirty five children(21 boys, 14 girls) were treated with VGB monotherapy. The mean age of patients at diagnosis was 3.21?.13 years, and the mean weight SDS at diagnosis was -0.19?.09. After the administration of VGB, the mean weight SDS was significantly increased (P<0.05). Increase in the mean weight SDS was significant in children with negative mean weight SDS at diagnosis, idiopathic epilepsy, partial seizure, and also significant in children below 6 years old. Mean weight SDS was not correlated with the dose of VGB administration after VGB monotherapy(P>0.05).
Conclusion
: VGB monotherapy significantly affects weight gain of patients treated for epilepsy. Strategies, such as optimizing diet and establishing an exercise routine, should be devised to help patients avoid weight gain when starting on VGB. It may be prudent to avoid, where possible, combinations of VGB with other antiepileptic drugs(such as valproate, carbamazepine gabapentin) which can lead to weight gain.

Keywords :Vigabatrin monotherapy, Mean weight standard deviation score

Go to Top